Core Insights - Whales have adopted a bearish stance on DexCom, with 62% of trades being bearish and only 25% bullish [1] - The major market movers are focusing on a price band between $40.0 and $70.0 for DexCom over the last three months [2] - DexCom's options trading volume and open interest indicate significant liquidity and interest within the specified price range [3] Options Activity - A total of 8 trades were detected, with 2 puts amounting to $370,845 and 6 calls totaling $506,319 [1] - The largest options trades include bearish puts and calls, with notable trades at strike prices of $55.00 and $65.00 [8] - The current volume of options trading for DexCom is substantial, with a snapshot indicating significant activity [4][6] Company Overview - DexCom specializes in continuous glucose monitoring systems for diabetic patients, providing an alternative to traditional blood glucose meters [9] - The company is evolving its systems to integrate with insulin pumps for automatic insulin delivery [9] Market Position - Professional analysts have set an average target price of $84.0 for DexCom, with individual targets ranging from $75.0 to $95.0 [10][11] - The current stock price of DXCM is $57.71, reflecting a 5.23% increase [13]

Core Insights - DexCom, Inc. (DXCM) is positioned for growth in the continuous glucose monitoring (CGM) market, with a strong third-quarter performance and favorable coverage decisions expected to drive further growth, despite facing stiff competition [1][2] Company Overview - DexCom has a market capitalization of $21.45 billion and projects a 22.5% growth rate over the next five years, indicating strong future performance [2] - The company has surpassed earnings estimates in two of the last four quarters, with an average surprise of 0.17% [2] CGM Market Potential - The diabetes market presents significant potential, with over 130 million people in the U.S. and more than 400 million globally affected by diabetes, driving demand for CGM devices [3] - The global CGM device market is expected to grow at a CAGR of nearly 10%, reaching $14 billion by 2032 from over $6 billion currently [4] Product Ecosystem and Innovation - DexCom generates nearly 90% of its revenue from disposable CGM sensors, with strong demand driven by product performance and user experience [6] - The G7 and One+ products are gaining traction due to broader insurance coverage and growing physician support, particularly among Type 2 diabetes patients [6] - DexCom's software ecosystem, including features like AI-powered insights, is enhancing patient engagement and supporting reimbursement efforts [7] Recent Developments - The launch of Stelo in 2024 has already generated over $100 million in its first year, indicating strong market acceptance [8] - DexCom is expanding global reimbursement for its CGM sensors, which is expected to drive broader adoption, especially among Type 2 diabetes patients [9] International Expansion - DexCom has made significant progress in international markets, securing reimbursements in countries like France, Canada, and Japan, which is expected to improve affordability and patient access [11] Financial Performance - DexCom reported strong third-quarter results with double-digit top-line growth and raised full-year guidance, reflecting successful execution in expanding access to CGM [12] - The Zacks Consensus Estimate for 2025 earnings per share has increased to $2.07, with fourth-quarter revenue expected to improve by 11.7% year over year [15]

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include those who purchased CarMax securities between June 20, 2025, and November 5, 2025 [1] Allegations of Misconduct - The complaint alleges that Defendants made false and/or misleading statements regarding CarMax's growth prospects, claiming that earlier growth was a temporary benefit due to customer speculation about tariffs [3] - It is asserted that the positive statements made by Defendants about the company's business and operations were materially misleading and lacked a reasonable basis [3] Lead Plaintiff Process - CarMax investors can seek to be appointed as a lead plaintiff representative of the class by January 2, 2026, or may choose to remain an absent class member [4] - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, during the period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7 device, including its reliability and accuracy, were overstated by the defendants [2]. - The lawsuit also contends that the true extent of the issues and health risks associated with the G7 devices was downplayed by the defendants [2]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants were characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs to be eligible for potential compensation [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]. - The firm has extensive experience in complex securities litigation, supported by a team of over 70 employees [4].

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between July 26, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] Company Details - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device, downplayed the severity of issues with the G7, and subjected DexCom to increased regulatory scrutiny and potential legal repercussions [3] - The lawsuit indicates that the public statements made by the defendants were materially false and misleading throughout the relevant time period [3] Next Steps - Shareholders who suffered losses in DexCom, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in DexCom securities [2]. - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell another $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed severe issues with the G7, leading to a nearly 12% drop of $8.99 per share [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 29, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [4] - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed risks related to the company's glucose monitoring products [1][3]. Summary by Sections Allegations - The complaint claims that during the class period from July 26, 2024, to September 17, 2025, DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were reportedly overstated by the defendants [3]. - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [3]. - As a result, the public statements made by the defendants were considered materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders who purchased shares of DXCM during the specified class period are encouraged to register for the class action by December 26, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) for violations of the federal securities laws on behalf of investors who purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). On October 27, 2025, a complaint was filed against the Company and cert ...